NCT03818386: Radiotherapy of Multiple Brain Metastases Using AGuIX

NCT03818386
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must be eligible for WBRT
Exclusions: Patients with leptomeningeal metastasis; Patients with previous cranial irradiation (except stereotactic irradiation)
https://ClinicalTrials.gov/show/NCT03818386

Comments are closed.

Up ↑